Aiming to improve on top-selling oncology drugs
This article was originally published in Start Up
These days, almost all cancers are treated with more than a single drug; the combinations typically include some type of chemotherapy and where possible an agent targeted at a particular mechanism known to be driving tumor growth. Clinicians are always striving to maximize the cancer-killing potential of a drug while minimizing the side effects caused by inherently toxic chemicals. The founders of Xcovery LLC are betting that anti-cancer compounds the firm is now developing will prove considerably less toxic than some of the most popular “targeted” oncology drugs prescribed today. If early clinical data bear out, the start-up anticipates that its orally available small molecules will eventually replace more toxic drugs frequently given in combinations, and so win market share from current leaders.
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.